post-transplant lymphoproliferative disorders
Conditions
Interventions
Experimental group:dornor lymphocyte infusion
Sponsors
the Second Hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
1 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1) All patients receiving allogeneic hematopoietic stem cell transplantation, regardless of age; 2) Positive EBV-IgG antibody from a healthy donor (essential); 3) Patients who cannot tolerate R+CHOP chemotherapy after transplantation; 4) Patients who refused R+CHOP chemotherapy after transplantation; 5) Patients who cannot afford the cost of rituximab due to financial circumstances; 6) Patients with at least clinically diagnosed EBV-PTLD after allogeneic hematopoietic stem cell transplantation; 7) Expected survival =3 months; 8) No serious complications, AST, ALT and bilirubin were less than 2.5 times of the upper limit of normal, serum creatinine was less than 2 times of the upper limit of normal, and myocardial enzymes were less than 2 times of the upper limit of normal within 2 weeks before admission; 9) No GVHD performance; 10) No active infection; 11) Women of childbearing age must have a negative pregnancy test and consent to the use of effective contraception during treatment and for one year thereafter.
Exclusion criteria
Exclusion criteria: 1) 0-IV GVHD patients 2) Patients with severe infection; 3) Patients with recurrent leukemia; 4) Exclude patients at high risk of bleeding (patients with clear risk of gastrointestinal bleeding, abnormal coagulation function, receiving thrombolysis and anticoagulation therapy); 5) Those who are participating in other clinical trials or have participated in other drug clinical trials within 3 months; 7) Lactating, or not taking effective contraceptive measures, or pregnant women; 8) Unstable mental state; 9) Patients considered unsuitable for this regimen by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;aGvHD rate;infection rate;Agranulocytic stage;thrombocytopenia rate ;immune reconstitution; | — |
Countries
CHINA
Contacts
Public ContactYan jinsong
The second hospital of dalian medical university
Outcome results
None listed